299 related articles for article (PubMed ID: 26015395)
1. Clinical next generation sequencing to identify actionable aberrations in a phase I program.
Boland GM; Piha-Paul SA; Subbiah V; Routbort M; Herbrich SM; Baggerly K; Patel KP; Brusco L; Horombe C; Naing A; Fu S; Hong DS; Janku F; Johnson A; Broaddus R; Luthra R; Shaw K; Mendelsohn J; Mills GB; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(24):20099-110. PubMed ID: 26015395
[TBL] [Abstract][Full Text] [Related]
2. Physician interpretation of genomic test results and treatment selection.
Brusco LL; Wathoo C; Mills Shaw KR; Holla VR; Bailey AM; Johnson AM; Khotskaya YB; Litzenburger BC; Sanchez NS; Zeng J; Bernstam EV; Eng C; Kee BK; Amaria RN; Routbort MJ; Mills GB; Mendelsohn J; Meric-Bernstam F
Cancer; 2018 Mar; 124(5):966-972. PubMed ID: 29165790
[TBL] [Abstract][Full Text] [Related]
3. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
4. A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory.
Arango NP; Brusco L; Mills Shaw KR; Chen K; Eterovic AK; Holla V; Johnson A; Litzenburger B; Khotskaya YB; Sanchez N; Bailey A; Zheng X; Horombe C; Kopetz S; Farhangfar CJ; Routbort M; Broaddus R; Bernstam EV; Mendelsohn J; Mills GB; Meric-Bernstam F
Oncotarget; 2017 Jun; 8(26):41806-41814. PubMed ID: 28415679
[TBL] [Abstract][Full Text] [Related]
5. High-throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing.
Bourgon R; Lu S; Yan Y; Lackner MR; Wang W; Weigman V; Wang D; Guan Y; Ryner L; Koeppen H; Patel R; Hampton GM; Amler LC; Wang Y
Clin Cancer Res; 2014 Apr; 20(8):2080-91. PubMed ID: 24573554
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial.
Tran B; Brown AM; Bedard PL; Winquist E; Goss GD; Hotte SJ; Welch SA; Hirte HW; Zhang T; Stein LD; Ferretti V; Watt S; Jiao W; Ng K; Ghai S; Shaw P; Petrocelli T; Hudson TJ; Neel BG; Onetto N; Siu LL; McPherson JD; Kamel-Reid S; Dancey JE
Int J Cancer; 2013 Apr; 132(7):1547-55. PubMed ID: 22948899
[TBL] [Abstract][Full Text] [Related]
7. Development of a Center for Personalized Cancer Care at a Regional Cancer Center: Feasibility Trial of an Institutional Tumor Sequencing Advisory Board.
Lane BR; Bissonnette J; Waldherr T; Ritz-Holland D; Chesla D; Cottingham SL; Alberta S; Liu C; Thompson AB; Graveel C; MacKeigan JP; Noyes SL; Smith J; Lakhani N; Steensma MR;
J Mol Diagn; 2015 Nov; 17(6):695-704. PubMed ID: 26331835
[TBL] [Abstract][Full Text] [Related]
8. Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors.
Kou T; Kanai M; Yamamoto Y; Kamada M; Nakatsui M; Sakuma T; Mochizuki H; Hiroshima A; Sugiyama A; Nakamura E; Miyake H; Minamiguchi S; Takaori K; Matsumoto S; Haga H; Seno H; Kosugi S; Okuno Y; Muto M
Cancer Sci; 2017 Jul; 108(7):1440-1446. PubMed ID: 28440963
[TBL] [Abstract][Full Text] [Related]
9. On the Road to Precision Cancer Medicine: Analysis of Genomic Biomarker Actionability in 439 Patients.
Schwaederle M; Daniels GA; Piccioni DE; Fanta PT; Schwab RB; Shimabukuro KA; Parker BA; Kurzrock R
Mol Cancer Ther; 2015 Jun; 14(6):1488-94. PubMed ID: 25852059
[TBL] [Abstract][Full Text] [Related]
10. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
[TBL] [Abstract][Full Text] [Related]
11. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
Cheng DT; Mitchell TN; Zehir A; Shah RH; Benayed R; Syed A; Chandramohan R; Liu ZY; Won HH; Scott SN; Brannon AR; O'Reilly C; Sadowska J; Casanova J; Yannes A; Hechtman JF; Yao J; Song W; Ross DS; Oultache A; Dogan S; Borsu L; Hameed M; Nafa K; Arcila ME; Ladanyi M; Berger MF
J Mol Diagn; 2015 May; 17(3):251-64. PubMed ID: 25801821
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of extensive molecular profiling in advanced cancer patients.
Cousin S; Grellety T; Toulmonde M; Auzanneau C; Khalifa E; Laizet Y; Tran K; Le Moulec S; Floquet A; Garbay D; Robert J; Hostein I; Soubeyran I; Italiano A
J Hematol Oncol; 2017 Feb; 10(1):45. PubMed ID: 28179005
[TBL] [Abstract][Full Text] [Related]
13. Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.
Takenaka M; Saito M; Iwakawa R; Yanaihara N; Saito M; Kato M; Ichikawa H; Shibata T; Yokota J; Okamoto A; Kohno T
Int J Oncol; 2015; 46(6):2389-98. PubMed ID: 25846456
[TBL] [Abstract][Full Text] [Related]
14. Personalized genomic analyses for cancer mutation discovery and interpretation.
Jones S; Anagnostou V; Lytle K; Parpart-Li S; Nesselbush M; Riley DR; Shukla M; Chesnick B; Kadan M; Papp E; Galens KG; Murphy D; Zhang T; Kann L; Sausen M; Angiuoli SV; Diaz LA; Velculescu VE
Sci Transl Med; 2015 Apr; 7(283):283ra53. PubMed ID: 25877891
[TBL] [Abstract][Full Text] [Related]
15. Comparative genomic analysis of primary tumors and metastases in breast cancer.
Bertucci F; Finetti P; Guille A; Adélaïde J; Garnier S; Carbuccia N; Monneur A; Charafe-Jauffret E; Goncalves A; Viens P; Birnbaum D; Chaffanet M
Oncotarget; 2016 May; 7(19):27208-19. PubMed ID: 27028851
[TBL] [Abstract][Full Text] [Related]
16. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Stockley TL; Oza AM; Berman HK; Leighl NB; Knox JJ; Shepherd FA; Chen EX; Krzyzanowska MK; Dhani N; Joshua AM; Tsao MS; Serra S; Clarke B; Roehrl MH; Zhang T; Sukhai MA; Califaretti N; Trinkaus M; Shaw P; van der Kwast T; Wang L; Virtanen C; Kim RH; Razak AR; Hansen AR; Yu C; Pugh TJ; Kamel-Reid S; Siu LL; Bedard PL
Genome Med; 2016 Oct; 8(1):109. PubMed ID: 27782854
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.
Meric-Bernstam F; Brusco L; Shaw K; Horombe C; Kopetz S; Davies MA; Routbort M; Piha-Paul SA; Janku F; Ueno N; Hong D; De Groot J; Ravi V; Li Y; Luthra R; Patel K; Broaddus R; Mendelsohn J; Mills GB
J Clin Oncol; 2015 Sep; 33(25):2753-62. PubMed ID: 26014291
[TBL] [Abstract][Full Text] [Related]
18. Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study-An Asian Tertiary Cancer Center Experience.
Seet AOL; Tan AC; Tan TJ; Ng MCH; Tai DWM; Lam JYC; Tan GS; Gogna A; Too CW; Tan BS; Takano A; Lim A; Lim TH; Lim ST; Dent RA; Ang MK; Yap YS; Tan IBH; Choo SP; Toh CK; Lim EH; Farid M; Skanderup AJ; Iyer NG; Lim WT; Tan EH; Lim TKH; Tan DSW
JCO Precis Oncol; 2021; 5():. PubMed ID: 34250396
[TBL] [Abstract][Full Text] [Related]
19. A system for detecting high impact-low frequency mutations in primary tumors and metastases.
Anjanappa M; Hao Y; Simpson ER; Bhat-Nakshatri P; Nelson JB; Tersey SA; Mirmira RG; Cohen-Gadol AA; Saadatzadeh MR; Li L; Fang F; Nephew KP; Miller KD; Liu Y; Nakshatri H
Oncogene; 2018 Jan; 37(2):185-196. PubMed ID: 28892047
[TBL] [Abstract][Full Text] [Related]
20. Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.
Ibarrola-Villava M; Fleitas T; Llorca-Cardeñosa MJ; Mongort C; Alonso E; Navarro S; Burgues O; Vivancos A; Cejalvo JM; Perez-Fidalgo JA; Roselló S; Ribas G; Cervantes A
Oncotarget; 2016 Apr; 7(16):22543-55. PubMed ID: 26968814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]